ライフサイエンスコーパス: acarbose

1 se, being almost 9 times more effective than acarbose.

2 with EC(50) values lower than that found for acarbose.

3 s effective as the pharmaceutical inhibitor, acarbose.

4 pha-amylase in vitro, comparable to the drug acarbose.

5 erium thermosaccharolyticum with and without acarbose.

6 lase, being nearly as potent an inhibitor as acarbose.

7 f inhibition was assessed in comparison with acarbose.

8 centralised computer system to receive oral acarbose (50 mg three times a day) or matched placebo, w

9 al structures of the two enzymes soaked with acarbose, a transition-state analog.

10 g bead immobilization and lectin analysis of acarbose, an antidiabetic drug, to dabsyl-tagged enzyme

11 Complexes of the enzyme with acarbose and 1-dexoynojirimycin and two different covale

12 ention-to-treat population, 3272 assigned to acarbose and 3250 to placebo.

13 xtracts potentiated the inhibition caused by acarbose and could replace the inhibition lost by reduci

14 ymethyl group of the nonreducing end of both acarbose and D-gluco-dihydroacarbose toward a more axial

15 Acarbose and lactulose were used to examine the disaccha

16 and glucose transport were not inhibited by acarbose and that the presence of glucose induced lactul

17 he mechanisms underlying the synergy between acarbose and the berry polyphenols and the lack of syner

18 n the presence of four different inhibitors: acarbose and three sulfonium ion compounds.

19 ex soaked with the tetrasaccharide inhibitor acarbose, at 1.9 A, reveal a decasaccharide moiety, span

20 transition state analog acarviosine-glucose-acarbose, at resolutions down to 2.1 A.

21 emonstrating that the glucoamylase inhibitor acarbose binds PhK, perturbs its structure, and stimulat

22 The Acarbose Cardiovascular Evaluation (ACE) trial was a ran

23 The crystal structure of HSAmy-ar as an acarbose complex was determined at a resolution of 1.5 A

24 5 A and compared with the existing wild-type acarbose complex.

25 tallographic analysis of the enzyme in free, acarbose-complexed, and trapped 5-fluoro-beta-glucosyl-e

26 We aimed to assess whether acarbose could reduce the frequency of cardiovascular ev

27 nits, clearly demonstrates synthesis of this acarbose-derived decasaccharide by a two-step transglyco

28 tes in the structure of W58A in complex with acarbose-derived pseudooligosaccharide.

29 eart disease and impaired glucose tolerance, acarbose did not reduce the risk of major adverse cardio

30 replace the inhibition lost by reducing the acarbose dose.

31 uctose-glucose (FruGlu) and fructose-glucose-acarbose (FruGluA) solutions than from fructose-mannitol

32 ose-mannitol (FruMann) and fructose-mannitol-acarbose (FruMannA) solutions, but there was no differen

33 Diabetes developed less frequently in the acarbose group (436 [13%] of 3272; 3.17 per 100 person-y

34 470 (14%; 3.33 per 100 person-years) of 3272 acarbose group participants and in 479 (15%; 3.41 per 10

35 se changes (215 [7%] of 3263 patients in the acarbose group vs 150 [5%] of 3241 in the placebo group

36 Analysis of the complex of GTase with acarbose has revealed the locations of five sugar-bindin

37 ima GTase and its complex with the inhibitor acarbose have been determined at 2.6A and 2.5A resolutio

38 tetrasaccharides D-gluco-dihydroacarbose and acarbose have been refined to R-factors of 0.147 and 0.1

39 ucosidase inhibitors than the clinical drug, acarbose (IC(50)=200muM).

40 gh only Trp120 is indicated to interact with acarbose in the crystal structure.

41 -dihydroacarbose (K1 = 10(-8) M) relative to acarbose (K1 = 10(-12) M) may stem in part from the weak

42 he effect of the alpha-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with cor

43 extracts exhibited the potential to replace acarbose (or reduce the dose required) in its current cl

44 (P < 0.05) sucrose absorption than a sucrose-acarbose solution.

45 ural products, such as the antidiabetic drug acarbose, the crop protectant validamycin, and the natur

46 Acarbose, the dipeptidyl-peptidase 4-inhibitor sitaglipt

47 lidamycin A biosynthesis, as well as that of acarbose, the valienamine and validamine moieties are ul

48 tion therapy of metformin, glipizide XL, and acarbose to lower A1C to 6.7% and 2-day repeated hypogly

49 Both enzymes modify acarbose upon binding through hydrolysis, condensation o